Menu

DESCRIPTION:

Fortez contains Ceftazidime, a semisynthetic, third generation, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. 

COMPOSITION:

Fortez 1g IM/IV Injection:

Vial: Ceftazidime Pentahydrate equivalent to Ceftazidime 1g

Ampoule: Water for injection 10mL

Fortez Injection 500mg IM/IV:

Vial: Ceftazidime Pentahydrate equivalent to Ceftazidime 500mg

Ampoule: Water for injection 5mL

Fortez Injection 250mg IM/IV:

Vial: Ceftazidime Pentahydrate equivalent to Ceftazidime 250mg

Ampoule: Water for injection 5mL

INDICATIONS:

Fortez (Ceftazidime) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases:

1. Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Hemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains).

2. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains).

3. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli.

4. Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant).

5. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae.

6. Prophylaxis for transurethral resection of prostate

7. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Hemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains).

8. Post-surgical Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci).

9. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole positive Proteus; Klebsiella spp.; and Escherichia coli.

10. Febrile neutropenia

11. Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria, caused by pseudomonas species

It may be used alone in cases of confirmed or suspected sepsis. it may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient’s condition.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Fortez and other antibacterial drugs, Fortez should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

DOSAGE AND ADMINISTRATION:

Adult
Usual recommended dosage1 gram intravenous or intramuscularevery 8 to 12 hours
Uncomplicated urinary tract infection250 mg intravenous or intramuscularevery 12 hours
Bone and joint infections2 grams intravenousevery 12 hours
Complicated urinary tract infections500 mg intravenous or intramuscularevery 8 to 12 hours
Uncomplicated pneumonia; mild skin and skin-structure infections500 mg to 1 gram intravenous or intramuscularevery 8 hours
Serious gynecological and intra-abdominal infections2 grams intravenousevery 8 hours
Meningitis2 grams intravenousevery 8 hours
Very severe life-threatening infections, especially in immunocompromised patients2 grams intravenousevery 8 hours
Lung infections caused by Pseudomonas spp. in patients with cystic fibrosis with normal renal function *30 to 50 mg/kg intravenous to a maximum of 6 grams per dayevery 8 hours
Neonates (0-4 weeks)30 mg/kg intravenousevery 12 hours
Infants and children (1 month – 12 years)30 to 50 mg/kg intravenous to a maximum of 6 grams per day tevery 8 hours

PRESENTATION:

Fortez 2g IM/IV Injection:

Vial containing powder and ampoule with 10mL water for injection

Fortez 1g IM/IV Injection:

Vial containing powder and ampoule with 10mL water for injection

Fortez 500mg IM/IV Injection: 

Vial containing powder and ampoule with 5mL water for injection

Fortez 250mg IM/IV Injection:

Vial containing powder and ampoule with 10mL water for injection

expand_less